Vanguard Group Inc. Purchases 16,095 Shares of Insulet Co. (NASDAQ:PODD)

Vanguard Group Inc. boosted its holdings in shares of Insulet Co. (NASDAQ:PODD) by 0.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,489,976 shares of the medical instruments supplier’s stock after acquiring an additional 16,095 shares during the quarter. Vanguard Group Inc. owned approximately 12.10% of Insulet worth $2,216,478,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in PODD. SBI Securities Co. Ltd. bought a new position in shares of Insulet during the 4th quarter valued at $36,000. SRS Capital Advisors Inc. raised its holdings in Insulet by 43.1% during the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 56 shares in the last quarter. Friedenthal Financial acquired a new stake in shares of Insulet in the fourth quarter worth about $57,000. TD Private Client Wealth LLC boosted its stake in shares of Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 56 shares in the last quarter. Finally, Assetmark Inc. increased its holdings in shares of Insulet by 1,447.1% during the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock valued at $69,000 after acquiring an additional 246 shares during the last quarter.

Insulet Trading Down 2.9 %

PODD stock opened at $264.88 on Thursday. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The firm has a market cap of $18.60 billion, a P/E ratio of 45.75, a P/E/G ratio of 3.62 and a beta of 1.29. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The business’s 50 day moving average is $272.28 and its 200-day moving average is $258.24.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. Equities analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the transaction, the director now owns 3,231 shares of the company’s stock, valued at $888,525. This trade represents a 36.10 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on PODD. Wells Fargo & Company upped their target price on Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Piper Sandler lifted their target price on shares of Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. StockNews.com cut shares of Insulet from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Raymond James reiterated an “outperform” rating and issued a $328.00 price objective (up from $294.00) on shares of Insulet in a research note on Friday, February 21st. Finally, Royal Bank of Canada began coverage on Insulet in a research note on Thursday, March 6th. They set an “outperform” rating and a $340.00 target price for the company. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $292.06.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.